Physician profile
Chad A Mongrain
NPI 1720028244
$835.58
in general payments reported to CMS, 2019-2025
14 companies · $62.29 in 2025
The $62.29 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $50.20 · 2021: $12.91 · 2022: $35.47 · 2023: $91.45 · 2024: $207 · 2025: $62.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.96 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $182.70 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $147.27 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $107.14 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $53.21 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $31.25 | 2019 | |
| Lilly USA, LLC | $24.65 | 2019 | |
| Sanofi Pasteur INC. | $22.14 | 2019 | |
| Abbvie INC. | $21.41 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.36 | 2020 | |
| Amarin Pharma, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Mongrain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.